Inozyme Pharma Inc. CEO Discusses Clinical-Stage Therapies in Rare Diseases at Bank of America Health Care Conference

Inozyme Pharma Inc. is a clinical-stage rare disease biopharmaceutical company that is focused on developing novel therapeutics for the treatment of diseases affecting the vasculature, soft tissue, and skeleton. The company’s CEO and Chairman, Doug Treco, Ph.D., will be participating in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024.

INZ-701 is an enzyme replacement therapy that Inozyme is currently working on to address pathologic mineralization and intimal proliferation that can lead to severe health issues. This therapy is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

For more information about Inozyme Pharma Inc., visit their website at or follow them on LinkedIn, Twitter, and Facebook. Investors can contact Stefan Riley, Senior Director of IR and Corporate Communications at (857) 330-8871 or email stefan.riley@inozyme.com. Media inquiries can be directed to Matt Pera at SmithSolve by calling (973) 886-9150 or emailing matt.pera@smithsolve>.